Effect of calcium citrate vs calcium carbonate on elevated parathyroid hormone after Roux-en-Y gastric bypass. A double-blinded, randomized trial.

Abstract

Following Roux-en-Y gastric bypass (RYGB), elevated parathyroid hormone (PTH) levels potentially harmful to bone health are commonly observed. Owing to assumed superior absorption, calcium citrate is often recommended over calcium carbonate following RYGB for the treatment of elevated PTH. We aimed to investigate the impact of either calcium carbonate or calcium citrate (1200mg elementary calcium) in patients with elevated PTH levels following RYGB. Clinical, double-blinded, randomized controlled trial of a 12-week duration at a Danish University Hospital. Thirty-nine (no drop out) RYGB operated patients with elevated PTH levels (PTH>6.9pmol/L) and normal plasma levels of calcium and 25-hydroxyvitamin D were randomized to either calcium carbonate or calcium citrate (1200mg elementary calcium/daily). We assessed change in PTH as the primary outcome. The effect of the two calcium formulations on change in PTH was comparable and neutral: -1.9% (calcium citrate) vs +0.9% (calcium carbonate), P=0.680. Compared to the carbonate-treated group, the following bone turnover markers decreased significantly in the citrate-treated group: procollagen I N-terminal propeptide (-16.6% vs -3.2%, P=0.021), osteocalcin (-17.2% vs -4.3%, P=0.007) and bone-specific alkaline phosphatase (-5.9% vs 3.7%, P=0.027) and remained significantly decreased after multivariable adjustment. Increasing the dose of calcium supplementation in RYGB operated patients with slightly elevated PTH levels does not normalize PTH levels, regardless of the type of supplement. Our results do not support recommending supplementation with calcium citrate over calcium carbonate in RYGB patients.